Evogliptin Tartrate
Evogliptin Tartrate 用途与合成方法
DPP-4
Evogliptin tartrate significantly inhibits the TNF-α-mediated induction of ICAM-1 and VCAM-1 expression in a concentration-dependent manner (IC
50
= 0.30 and 0.25 μM, respectively).
Evogliptin tartrate inhibits the TNF-α-mediated transcriptional activation of ICAM-1 and VCAM-1.
Evogliptin tartrate inhibits inflammatory responses via suppression of adhesion molecules induced by TNF-α. And TNF-α-mediated activation of NF-κB is ameliorated by evogliptin via the interaction of NF-κB with SIRT1.
Cell Viability Assay
| Cell Line: | Endothelial cells |
| Concentration: | 0.1 μM, 0.3 μM, 1 μM, 3 μM |
| Incubation Time: | 12 hours |
| Result: | Inhibits TNF-α-mediated (10 ng/ml) expression of adhesion molecules. |
Evogliptin tartrate (37.5-150 mg/kg; p.o.; daily; for 12 weeks) reduces the high-fat diet-induced atherosclerotic plaque area in the ApoE
−/−
mouse model.
Evogliptin tartrate inhibits the formation of atherosclerotic lesions by reducing vasoinflammation and increases plaque stability.
| Animal Model: | ApoE −/− mice |
| Dosage: | 37.5 mg/kg, 75 mg/kg, 150 mg/kg |
| Administration: | Oral administration; daily; for 12 weeks |
| Result: | Inhibit the development of atherosclerosis. |
Evogliptin Tartrate 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2026-09-15 | HY-117985B | 1222102-51-3 | 1 mg | 1000 | |
| 2026-09-15 | HY-117985B | Evogliptin Tartrate | 1222102-51-3 | 5mg | 2800 |
